Market closedNon-fractional
Clene/CLNN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Clene
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements).
Ticker
CLNN
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Salt Lake City, United States
Employees
84
Website
clene.com
Clene Metrics
BasicAdvanced
$45M
Market cap
-
P/E ratio
-$0.41
EPS
-
Beta
-
Dividend rate
Price and volume
Market cap
$45M
Financial strength
Current ratio
1.226
Quick ratio
1.123
Long term debt to equity
276.853
Total debt to equity
760.788
Interest coverage (TTM)
-8.24%
Management effectiveness
Return on assets (TTM)
-57.44%
Return on equity (TTM)
-3,702.24%
Valuation
Price to revenue (TTM)
66.394
Price to book
10.54
Price to tangible book (TTM)
10.54
Price to free cash flow (TTM)
-1.465
Growth
Revenue change (TTM)
12.73%
Earnings per share change (TTM)
-0.01%
3-year revenue growth
21.11%
3-year earnings per share growth
-40.31%
What the Analysts think about Clene
Analyst Ratings
Majority rating from 5 analysts.
Clene Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
-100.00%
Net income
-$11M
8.91%
Profit margin
0.00%
-100.00%
Clene Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.29
-$0.02
-$0.06
-$0.09
-
Expected
-$0.12
-$0.09
-$0.07
-$0.08
-$0.08
Surprise
136.05%
-77.78%
-17.24%
12.50%
-
Clene News
AllArticlesVideos
Clene to Present at H.C. Wainwright's 5th Annual Neuro Perspectives Virtual Conference
GlobeNewsWire·2 weeks ago
Clene Presents Preliminary Data for CNM-Au8® as a Potential Treatment for Rett Syndrome
GlobeNewsWire·2 weeks ago
Clene Presents Extended Survival Data Through 3.5 Years and New NfL Responder Results with CNM-Au8® 30 mg Treatment from the HEALEY ALS Platform Trial Open Label Extension at the 2024 ENCALS Meeting
GlobeNewsWire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Clene stock?
Clene (CLNN) has a market cap of $45M as of July 06, 2024.
What is the P/E ratio for Clene stock?
The price to earnings (P/E) ratio for Clene (CLNN) stock is 0 as of July 06, 2024.
Does Clene stock pay dividends?
No, Clene (CLNN) stock does not pay dividends to its shareholders as of July 06, 2024.
When is the next Clene dividend payment date?
Clene (CLNN) stock does not pay dividends to its shareholders.
What is the beta indicator for Clene?
Clene (CLNN) does not currently have a Beta indicator.
Buy or sell Clene stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.